Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. News
  7. Summary
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EXAGEN INC. : Results of Operations and Financial Condition (form 8-K)

11/10/2021 | 04:09pm EST

Item 2.02. Results of Operations and Financial Condition. On November 10, 2021, the Company reported its financial results for the three and nine months ended September 30, 2021. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report. The information furnished with Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits

  Exhibit No.          Description

99.1                     Press Release dated November 10, 2021

104                    Cover Page Interactive Data File (embedded within the Inline XBRL document)



--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about EXAGEN INC.
01/10EXAGEN INC. : Regulation FD Disclosure (form 8-K)
AQ
01/10Exagen, Queen Mary University to Collaborate on Molecular Signatures for Rheumatoid Art..
MT
01/09Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collabor..
AQ
01/09Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collabor..
CI
2021Exagen Inc. to Participate in the Piper Sandler 33rdáAnnual Virtual Healthcare Conferen..
GL
2021Exagen Inc. to Participate in the Piper Sandler 33rdáAnnual Virtual Healthcare Conferen..
GL
2021KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating
MT
2021EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2021Exagen Inc. Reports Third Quarter 2021 Results - Form 8-K
PU
2021Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $12.3M, vs. Street Est of $12.1M
MT
More news
Analyst Recommendations on EXAGEN INC.
More recommendations